Tizanidine Hydrochloride Capsule
Product Images NDC 85742-032

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 85742-032). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kanchan Healthcare Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cont-label-2-mg-150-capsules (Cont Label 2 mg 150 Capsules)

Each capsule contains 220 mg tizanidine hydrochloride, equivalent to 2 mg tizanidine base. The recommended storage temperature is between 68°F to 77°F, with excursions permitted between 59°F to 86°F. The usual dosage information can be found in the package insert. Dispense in containers with child-resistant closures. Keep this medication out of reach of children. Zandile® is a registered trademark of ACOTA Therapeutics Inc. Manufactured by Cadila Pharmaceuticals Limited in Gujarat, India, and marketed by Kanchan Healthcare Inc. in Parsippany, NJ, USA. This text also includes manufacturing and marketing license information.*

FDA Label Image

Cont-label-4-mg-150-capsules (Cont Label 4 mg 150 Capsules)

FDA Label Image

Cont-label-6-mg-150-capsules (Cont Label 6 mg 150 Capsules)

FDA Label Image

Tizanidine-spl-structure (Structure Tizanidine)

FDA Label Image

Figure-1 (Tizanidine Spl Fig 1)

FDA Label Image

Figure-2 (Tizanidine Spl Fig 2)

This information appears to show the comparison of the improvement in Ashworth Score between different doses of tizanidine (16 mg and 8 mg) and a placebo over time. The graph likely displays the time points post-dose on the x-axis.*

FDA Label Image

Figure-3 (Tizanidine Spl Fig 3)

This text mentions an improvement in Ashworth Score, comparing the effects of Tizanidine with a placebo in a study that lasted up to 7 weeks. The mean dose of Tizanidine administered was 28.8 mg. The evaluation was carried out at the end of titration (Study Week 3) and the end of maintenance endpoint (Study Week 7) using the Last Observation Carried Forward method.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.